Inserm U975, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, CR-ICM, Paris, France.
Stem Cells. 2010 Sep;28(9):1611-22. doi: 10.1002/stem.480.
The basic helix-loop-helix transcription factors Olig1 and Olig2 are required for oligodendrocyte specification and differentiation during central nervous system (CNS) development but the effects of overexpression of these factors in murine development are not well understood. To test whether Olig1 and Olig2 may reprogram CNS stem/progenitors toward an oligodendroglial fate for myelination, we generated transgenic mice with doxycycline (Dox)-inducible expression of Olig1 or Olig2 in nestin-expressing stem/progenitor cells of the CNS. Overexpression of Olig1 or Olig2 from E8.5 to E12.5 was sufficient to promote the generation of platelet-derived growth factor receptor alpha + oligodendrocyte precursors (OPCs) in the spinal cord. We also demonstrated that overexpression of Olig2, but not Olig1, enhanced the stem/progenitor cell proliferation and generation of motoneuron precursors and inhibited the development of V3 interneurons. In the postnatal brain, Dox-inducible expression of Olig2 but not Olig1 in nestin+ stem/progenitors of the subventricular zone increased the generation of OPCs that migrated and differentiated into mature oligodendrocytes in the corpus callosum, cortex and olfactory bulb, leading to increased and precocious myelination. Altogether, our data indicate that Olig2 is a potential therapeutic target to enhance myelination and remyelination in the CNS.
基本螺旋-环-螺旋转录因子 Olig1 和 Olig2 是中枢神经系统 (CNS) 发育过程中少突胶质细胞特化和分化所必需的,但这些因子在小鼠发育中的过表达的影响尚不清楚。为了测试 Olig1 和 Olig2 是否可以将 CNS 干细胞/祖细胞重新编程为少突胶质细胞以进行髓鞘形成,我们生成了在 nestin 表达的 CNS 干细胞/祖细胞中具有 Dox 诱导性表达 Olig1 或 Olig2 的转基因小鼠。从 E8.5 到 E12.5 过表达 Olig1 或 Olig2 足以促进血小板衍生生长因子受体 alpha + 少突胶质前体细胞 (OPC) 在脊髓中的生成。我们还证明,过表达 Olig2,但不是 Olig1,可增强干细胞/祖细胞的增殖和运动神经元前体的生成,并抑制 V3 中间神经元的发育。在出生后的大脑中,Dox 诱导性表达 Olig2,但不是 nestin+ 脑室下区的 Olig1,增加了 OPC 的生成,这些 OPC 迁移并在胼胝体、皮层和嗅球中分化为成熟的少突胶质细胞,导致髓鞘形成增加和提前出现。总之,我们的数据表明 Olig2 是增强 CNS 髓鞘形成和再髓鞘化的潜在治疗靶点。